Quang Nguyen, MD
Ophthalmology · la Jolla, CANPI 1689636250
Payments from drug & device makers
Across 1,073 payments — averaging $577.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$143K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$117K
- Aerie Pharmaceuticals, Inc.$116K
- Alcon$71K
- AbbVie$54K
- Glaukos Corporation$44K
- plus $75K from 22 others
What the payments were for
- Consulting fees$68,37211%
- Speaking & faculty fees$437,58272%
- Travel & lodging$65,76611%
- Food & beverage$29,8315%
- Education$6,0001%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 213 | $142,542 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 155 | $116,978 |
| Aerie Pharmaceuticals, Inc. | 127 | $116,465 |
| Alcon | 137 | $71,183 |
| AbbVie(2 entities) | 175 | $54,407 |
| Glaukos Corporation | 53 | $43,549 |
| Ivantis, Inc | 37 | $36,289 |
| Sight Sciences, Inc. | 38 | $15,128 |
| Novartis | 79 | $14,839 |
| Intuitive Surgical | 2 | $6,000 |
| Apellis Pharmaceuticals, Inc. | 5 | $500 |
| Rxsight Inc | 4 | $289 |
| Amgen(2 entities) | 9 | $259 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $241 |
| Carl Zeiss Meditec USA, Inc. | 2 | $223 |
| Mallinckrodt Hospital Products Inc. | 8 | $200 |
| Regeneron Healthcare Solutions, Inc. | 5 | $167 |
| Nova Eye, Inc. | 2 | $140 |
| Thea Pharma Inc. | 5 | $102 |
| Carl Zeiss Meditec, Inc. | 2 | $60 |
| Harrow Eye, LLC | 2 | $57 |
| Kala Pharmaceuticals, Inc. | 3 | $54 |
| Dompe US, Inc. | 1 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Vertiflex, Inc. | 1 | $21 |
| Immunocore Limited | 1 | $20 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$248,499
- Rocklatan$161,712
- Rhopressa$150,716
- LUMIGAN$42,001
- Hydrus Microstent$23,200
- iStent inject Trabecular Micro-Bypass Stent System$22,682
- Hydrus$20,186
- TRAVATAN Z$13,671
- SIMBRINZA$11,830
- iStent Trabecular Micro-Bypass Stent System$9,136
- COMBIGAN$8,565
- OMNI(R) SURGICAL SYSTEM (US)$7,643
- OMNI$6,704
- Travoprost Intraocular Implant - iDose$6,125
- Da Vinci Surgical System$6,000
- ALPHAGAN P$4,931
- LOTEMAX SM$3,000
- iDoseTR$2,760
- iDose Trio$2,400
- iDose$1,969
How this compares
$619,809 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 627 | $359,865 |
| VyzultaLatanoprostene Bunod | 242 | $111,874 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $47,358 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 90 | $31,137 |
| Travoprost | 137 | $28,168 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $28,057 |
| Latanoprost | 1,797 | $26,921 |
| RhopressaNetarsudil Mesylate | 53 | $24,293 |
| Alphagan PBrimonidine Tartrate | 40 | $17,775 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 67 | $15,728 |
| Prednisolone Acetate | 444 | $13,277 |
| Timolol Maleate | 330 | $10,181 |
| Brinzolamide | 53 | $9,969 |
| AzoptBrinzolamide | 15 | $9,956 |
| Travatan ZTravoprost | 16 | $7,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $54,407 | $405,697732 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $142,542 | $111,874242 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $116,465 | $71,651130 claims |
| AlconSimbrinza, Azopt | $71,183 | $41,093105 claims |
| NovartisTravatan Z | $14,839 | $7,63316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in la Jolla
- Nikolas Londonla Jolla$6.1M
- Sasan Moghimi Araghila Jolla$883K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.